Zydus Lifesciences receives USFDA approval for Methenamine Hippurate tablets
Approval allows Zydus to manufacture and market 1-gram Methenamine Hippurate tablets in the United States
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Zydus Lifesciences
Zydus launches ANVIMO for prevention of CMV
Zydus has reduced the cost of Letermovir by 91 per cent of the innovator price. ANVIMO will be available in dosages of 240 mg and…
Zydus, supported by Gates Foundation, to develop combination vaccine against shigellosis and typhoid
This combination of vaccines, if found successful, will safeguard children against two lethal enteric diseases of global…
Zydus launches India’s first flu vaccine for southern hemisphere 2025 strain
VaxiFlu-4 developed as per WHO-recommended composition for influenza protection
Zydus Lifesciences partners with Zhuhai Beihai Biotech for BEIZRAY commercialisation in the US
Zydus to handle US market launch of Albumin Solubilized Docetaxel injection
Zydus Lifesciences signs agreement with Synthon BV for 505(B)(2) oncology product
Zydus to handle NDA submission and commercialisation in the US; Synthon to lead development and manufacturing
The 6th X-CIPLOG reunion event 2025 was held in Mumbai
X-CIPLOG Reunion 2025 and Excellence Awards reflect industry recognition resonating with the government’s padma bhushan honour to…
USFDA designates Zydus’ Usnoflast an orphan drug for ALS treatment
Usnoflast (ZYIL1) is a novel, oral small-molecule NLRP3 inhibitor. It has been studied in several pre-clinical models of…
Nadda urges industry, academia collaboration to build better healthcare at Healthcare Summit at IIMA
The event featured panel discussions like “Advancing Healthcare for India @ 2047” and “Transforming Healthcare – Insights from…
Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral…
This study consists of a 36-week treatment phase, followed by a 16-week open-label extension. The change in ALSFRS-R total score…